Ad is loading...
ALLO
Price
$2.27
Change
-$0.19 (-7.72%)
Updated
Nov 15 closing price
101 days until earnings call
KALV
Price
$9.49
Change
-$0.31 (-3.16%)
Updated
Nov 15 closing price
18 days until earnings call
Ad is loading...

ALLO vs KALV

Header iconALLO vs KALV Comparison
Open Charts ALLO vs KALVBanner chart's image
Allogene Therapeutics
Price$2.27
Change-$0.19 (-7.72%)
Volume$3.09M
CapitalizationN/A
KalVista Pharmaceuticals
Price$9.49
Change-$0.31 (-3.16%)
Volume$816.28K
CapitalizationN/A
ALLO vs KALV Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALLO vs. KALV commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Sell and KALV is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (ALLO: $2.27 vs. KALV: $9.49)
Brand notoriety: ALLO and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 142% vs. KALV: 198%
Market capitalization -- ALLO: $475.96M vs. KALV: $467.05M
ALLO [@Biotechnology] is valued at $475.96M. KALV’s [@Biotechnology] market capitalization is $467.05M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, KALV is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while KALV’s TA Score has 4 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 4 bearish.
  • KALV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than KALV.

Price Growth

ALLO (@Biotechnology) experienced а -26.30% price change this week, while KALV (@Biotechnology) price change was -16.83% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

KALV is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALLO($476M) and KALV($467M) have the same market capitalization . KALV YTD gains are higher at: -22.531 vs. ALLO (-29.283). KALV has higher annual earnings (EBITDA): -131.18M vs. ALLO (-256.56M). ALLO has more cash in the bank: 445M vs. KALV (210M). KALV has less debt than ALLO: KALV (7.32M) vs ALLO (87M). ALLO has higher revenues than KALV: ALLO (65K) vs KALV (0).
ALLOKALVALLO / KALV
Capitalization476M467M102%
EBITDA-256.56M-131.18M196%
Gain YTD-29.283-22.531130%
P/E RatioN/AN/A-
Revenue65K0-
Total Cash445M210M212%
Total Debt87M7.32M1,189%
FUNDAMENTALS RATINGS
ALLO vs KALV: Fundamental Ratings
ALLO
KALV
OUTLOOK RATING
1..100
6558
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
8064
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a43

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KALV's Valuation (49) in the Pharmaceuticals Other industry is somewhat better than the same rating for ALLO (97) in the Biotechnology industry. This means that KALV’s stock grew somewhat faster than ALLO’s over the last 12 months.

KALV's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ALLO (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to ALLO’s over the last 12 months.

ALLO's SMR Rating (95) in the Biotechnology industry is in the same range as KALV (96) in the Pharmaceuticals Other industry. This means that ALLO’s stock grew similarly to KALV’s over the last 12 months.

KALV's Price Growth Rating (64) in the Pharmaceuticals Other industry is in the same range as ALLO (80) in the Biotechnology industry. This means that KALV’s stock grew similarly to ALLO’s over the last 12 months.

KALV's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ALLO (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOKALV
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 14 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RWIIX14.34N/A
N/A
Redwood AlphaFactor Tactical Intl I
TRLCX23.69-0.06
-0.25%
Nuveen Large Cap Value Retire
HDVIX12.35-0.07
-0.56%
Hartford International Equity I
SRIAX14.15-0.08
-0.56%
Gabelli SRI A
CLSPX31.02-0.54
-1.71%
Columbia Select Mid Cap Gro Fd I

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-7.72%
FATE - ALLO
58%
Loosely correlated
-2.88%
NTLA - ALLO
56%
Loosely correlated
-7.61%
BEAM - ALLO
55%
Loosely correlated
-8.59%
CRSP - ALLO
54%
Loosely correlated
+0.85%
CRBU - ALLO
54%
Loosely correlated
-4.78%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with FATE. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-3.16%
FATE - KALV
45%
Loosely correlated
-2.88%
INZY - KALV
44%
Loosely correlated
-8.89%
PLRX - KALV
42%
Loosely correlated
-3.27%
ALLO - KALV
41%
Loosely correlated
-7.72%
IDYA - KALV
41%
Loosely correlated
-9.60%
More